Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, leading the British biotech to advance the next-generation cancer vaccine candidate rather than its older sibling. The phase 2 study enrolled patients with advanced melanoma to receive either SCIB1 or iSCIB1+ on top of Bristol Myers Squibb’s aging checkpoint inhibitors Opdivo and Yervoy. Tuesday, Scancell reported that the vaccines showed similar safety and efficacy in a phase 2 trial. Source: Fierce Biotech 22/7/2025